TScan Therapeutics Inc (TCRX)

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesJune 3, 2026 9:19 AM
Business Wire Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to commercialization Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced an agreement to evaluate automated clinical manufacturing of TSC-101, TScan's lead TCR-T therapy candidate for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), through a comprehensive technical and operational assessment of Cellares' automated manufacturing and testing platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603703141/en/Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 TSC-101 is designed to treat residual disease and prevent relapse in patients with AML and MDS undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The therapy candidate uses a gene modification approach to engineer T cells from a healthy donor into a patient-specific cell therapy product. As TScan advances TSC-101 towards a pivotal trial, which is expected to begin in the second quarter of 2026, the Company is evaluating Cellares’ automated manufacturing platform as a scalable and economical path to future commercial demand. Under the agreement, Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle, its end-to-end manufacturing platform, and the Cell Q, its automated quality control and release testing system. These closed-system, fully automated workflows are designed to reduce process variability, minimize labor intensity, and enable consistent execution across runs and geographies, delivering the manufacturing economics and reliability that large-scale commercial production requires. “As we prepare for the initiation of our pivotal study of TSC-101 this quarter, we are increasing our efforts for commercial readiness. Establishing a scalable and cost-efficient manufacturing strategy is a critical component. Cellares’ fully automated Cell Shuttle platform represents a promising approach to automating and scaling cell therapy production, with the potential to reduce manual processes and eliminate capacity constraints,” said Ray Lockard, M.B.A., Chief Manufacturing and Quality Officer of TScan Therapeutics. “Through this evaluation, we aim to determine how this technology could strengthen our long-term manufacturing network and support broader patient access, supporting our goal of delivering transformative therapies to patients as efficiently and reliably as possible.” "Patients with AML or MDS who remain at risk of relapse following transplant represent exactly the kind of underserved population that automated manufacturing was designed to reach,” said Fabian Gerlinghaus, Co-founder and Chief Executive Officer of Cellares. "Bringing automation to a late-stage program like TSC-101, with its healthy donor-derived but patient-specific manufacturing model, is the kind of challenge the Cell Shuttle and Cell Q were built for, and we believe it represents the manufacturing economics any developer will need to reach a population of this scale." The agreement adds TCR-engineered T cell therapies to Cellares’ growing portfolio of automated cell therapy modalities, which includes CAR-T cell therapies, hematopoietic stem cell programs, and autologous progenitor T cell therapies. About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company is also in early stages of developing methods for in vivo engineering to treat solid tumors. In addition, the Company is applying its target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders. About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO), providing global cell therapy development and manufacturing services through an Industry 4.0 approach to the mass manufacture of the living drugs of the 21st century. The company enables drug sponsors to develop, scale, and commercialize cell therapies with the capacity, reliability, and economics required to meet total patient demand. Cellares' fully automated platforms — Cell Shuttle? for end-to-end cell therapy manufacturing and Cell Q™ for automated in-process and release quality control — are deployed across its network of IDMO Smart Factories worldwide. These technologies deliver industry-leading manufacturing economics, higher process success rates, and the ability to produce up to 10× more cell therapy batches than conventional CDMOs with comparable footprint and headcount, resulting in the lowest cost of manufacturing in the industry. The Cell Shuttle is the first cell therapy manufacturing platform to receive the FDA's Advanced Manufacturing Technology (AMT) designation, and has demonstrated a 100% automation success rate across more than a dozen automated processes. Cellares has achieved key clinical validation milestones, including a successful IND Amendment enabling active clinical manufacturing on the Cell Shuttle platform, and the successful dosing of first patients in a partner clinical trial — marking the platform's transition from development-stage technology to clinically validated manufacturing infrastructure. These milestones span multiple therapeutic areas and cell therapy modalities, including both oncology and autoimmune indications. Headquartered in South San Francisco, California, Cellares operates its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, with additional facilities under construction in Europe and Japan. Through its global manufacturing network, Cellares is purpose-built to support both clinical and commercial programs and to expand access to life-saving cell therapies worldwide. For more information, visit www.cellares.com and follow Cellares on LinkedIn. TScan Therapeutics Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the structure, timing, economics, reliability, and overall success of TScan Therapeutics, Inc.'s ("TScan") agreement with Cellares; TScan’s plans, progress, and timing related to TScan’s hematologic malignancies program, including initiation of a pivotal trial for TSC-101; TScan’s planned preclinical development and clinical trials for any of its programs; the potential benefits of any of TScan’s proprietary platforms or current or future product candidates in treating patients; and TScan’s goals and strategy. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan,” “on track,” or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScan’s TCR-T therapy product candidates; TScan’s expectations regarding its preclinical studies being predictive of clinical trial results; TScan’s cleared INDs being indicative or predictive of bringing TScan closer to its goal of providing customized TCR-T therapies to treat patients with cancer; the timing of the launch, initiation, progress, expected results and announcements of TScan’s preclinical studies, clinical trials and its research and development programs; TScan’s ability to enroll patients for its clinical trials within its expected timelines; TScan’s plans relating to developing and commercializing its TCR-T therapy product candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScan’s TCR-T therapy product candidates; TScan’s manufacturing capabilities and the scalable nature of its manufacturing process; TScan’s estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScan’s expectations regarding competition; TScan’s anticipated growth strategies; TScan’s ability to attract or retain key personnel; TScan’s ability to establish and maintain development partnerships and collaborations; TScan’s expectations regarding federal, state and foreign regulatory requirements; TScan’s ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScan’s existing capital resources to fund its future operating expenses and capital expenditure requirements; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of TScan’s most recent Annual Report on Form 10-K and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScan’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements. View source version on businesswire.com: https://www.businesswire.com/news/home/20260603703141/en/ Cellares Contacts
Business Development: bd@cellares.com
Investors: ir@cellares.com
Media: pr@cellares.com TScan Contacts
Investors and Media:
Caileigh Dougherty
AVP, Head of Corporate Communications & Investor Relations
857-399-9890
cdougherty@tscan.com Original: Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

TCRX.........................https://stockcharts.com/sc3/ui/?s=TCRX&p=w&b=5&g=0&id=p86431144783

Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of CareMarch 19, 2026 10:00 AM
PR Newswire (US)

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ: ONCY), Gilead Sciences (NASDAQ: GILD), enGene Holdings (NASDAQ: ENGN), TScan Therapeutics (NASDAQ: TCRX), and Day One Biopharmaceuticals (NASDAQ: DAWN) (soon to be Servier), which are each advancing translational data or near-term regulatory milestones in the 2026 cycle.Goldman Sachs has projected 2026 will be a record-breaking year for biopharma dealmaking, with pharma and biotech companies remaining the primary target as a patent cliff looms which could result in the loss of hundreds of billions in revenue[3]. This structural shift creates a window for companies with asymmetric upside in high-value solid tumor markets, as the FDA's expanded accelerated approval framework—now covering gene therapies and next-generation combination regimens—compresses the timeline from translational data to commercial launch, making regulatory milestones the primary value driver for the 2026 immuno-oncology investment cycle[4].             Oncolytics Biotech (NASDAQ: ONCY) is presenting new mechanistic and translational data at the American Association for Cancer Research (AACR) Annual Meeting in San Diego this April, data that adds scientific depth to the company's push into some of cancer's hardest-to-treat corners.The two abstracts, drawn from the AWARE-1 breast cancer study and the GOBLET gastrointestinal cancer trial, both center on the same question: can pelareorep, the company's lead drug, make tumors more vulnerable to immunotherapy? The short answer, based on these findings, appears to be yes. In AWARE-1, biopsies showed pelareorep triggering the formation of tertiary lymphoid structures, essentially localized immune hubs that help the body mount a sustained attack on cancer cells.Tumors that would otherwise stay "cold" and invisible to the immune system showed signs of becoming "hot." In GOBLET Cohort 1, patients with pancreatic cancer who showed early immune activation after four weeks on a pelareorep-based regimen lived longer without their disease progressing than those who did not, 7.5 months compared to 5.6 months. That same treatment combination previously posted a 62% objective response rate in first-line pancreatic cancer patients, more than double what chemotherapy alone has historically produced.The data matter because they help explain the results Oncolytics has already reported in colorectal cancer, where the backdrop is equally encouraging. The company recently launched REO 033, a randomized Phase 2 trial testing pelareorep alongside bevacizumab and FOLFIRI in second-line RAS-mutated, microsatellite-stable metastatic colorectal cancer, a patient group with very few good treatment options today.The trial builds on earlier results from REO 022, where the same drug combination produced 27 months of overall survival, 11.2 months of progression-free survival, and a 33% objective response rate, against 16.6 months, 5.7 months, and roughly 10% for the standard of care. The FDA took notice, granting the regimen Fast Track Designation earlier this year. The second-line KRAS-mutant colorectal cancer market is estimated at $3 to $5 billion annually. REO 033 expects to open its first site next month, with preliminary data targeted for year-end 2026.Oncolytics is a clinical-stage biotechnology company that has spent years building a scientific case for pelareorep across multiple tumor types. Across anal cancer, pancreatic cancer, and now colorectal cancer, the drug is accumulating a consistent body of evidence as something that may make other gastrointestinal cancer treatments work better. That kind of backbone role, if confirmed in larger trials, could position Oncolytics as a meaningful partner in the broader immuno-oncology landscape, where combination strategies are increasingly where the field is heading.CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/In other industry developments:Gilead Sciences (NASDAQ: GILD) reported fourth quarter and full year 2025 financial results showing oncology revenues of $3.2 billion for the year, anchored by a 6% increase in Trodelvy sales to $1.4 billion on higher breast cancer demand, while Yescarta received a label update removing a limitation around Primary Central Nervous System Lymphoma, making it the only CAR-T therapy in relapsed or refractory large B-cell lymphoma to have that restriction lifted. The company also presented positive pivotal Phase 2 iMMagine-1 data for its Arcellx-partnered CAR T-cell therapy anitocabtagene autoleucel in 4L+ relapsed or refractory multiple myeloma at the 2025 American Society of Hematology meeting, with two additional cancer therapy launches anticipated in 2026."In 2026, our potential new launches include two cancer therapies and an additional HIV treatment option, and we look forward to building on the launches of Yeztugo and Livdelzi for liver disease," said Daniel O'Day, Chairman and CEO of Gilead Sciences.Gilead Sciences closed 2025 with $10.6 billion in cash and marketable debt securities and generated $10.0 billion in operating cash flow for the full year. For 2026, Gilead Sciences guides for total product sales of $29.6 billion to $30.0 billion and non-GAAP diluted EPS of $8.45 to $8.85, with anticipated oncology launches expected to contribute meaningfully to growth alongside continued HIV franchise momentum.enGene Holdings (NASDAQ: ENGN) reported Q1 2026 financial results reflecting continued advancement of its lead non-viral gene therapy candidate, detalimogene voraplasmid, toward a Biologics License Application submission targeted for the second half of 2026. The company's pivotal LEGEND cohort of 125 BCG-unresponsive NMIBC patients demonstrated a 63% complete response rate at any time and a 62% CR rate at 6 months, while enGene Holdings closed Q1 with $312.5 million in cash and marketable securities."As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference," said Ron Cooper, President and CEO of enGene Holdings. "With RMAT and CDRP designations for detalimogene, we are in active dialogue with the FDA to ensure regulatory and manufacturing readiness as we plan for a BLA submission in the second half of this year and potential launch in 2027."enGene Holdings expanded its Hercules Capital debt facility to $125 million in January 2026, providing additional non-dilutive capital ahead of its planned commercial launch. The company expects its current cash position to fund operations into the second half of 2028, and 12-month complete response data from the LEGEND pivotal cohort is expected in 2H 2026.TScan Therapeutics (NASDAQ: TCRX) reported Q4 and full year 2025 financial results while providing updates on its TCR-engineered T cell hematologic malignancies program, including the completion of enrollment in Cohort C of the Phase 1 ALLOHA trial and FDA clearance of INDs for two new CD45-targeting candidates, TSC-102-A01 and TSC-102-A03. Full year 2025 collaboration and license revenue reached $10.3 million versus $2.8 million in 2024, with cash and equivalents of $152.4 million expected to fund operations into 2H 2027."The regulatory and operational progress we have made over the last several months related to our heme program is exciting," said Gavin MacBeath, Ph.D., CEO of TScan Therapeutics. "We expect the momentum to continue into the second quarter when we plan to share the initial data from patients enrolled into Cohort C in the ALLOHA study as well as initiate TScan's first Phase 3 trial. The data we presented at ASH in December 2025 continue to support our decision to focus the Company's efforts on development of therapeutics for patients with heme malignancies. Additionally, the recent FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 will allow us to bring our TCR-T therapies to twice as many patients who currently have limited options in the post-transplant setting."TScan Therapeutics discontinued its PLEXI-T solid tumor trial in November 2025 to concentrate resources on hematologic malignancies, and anticipates sharing preclinical proof-of-concept data from its autoimmunity program in 2H 2026. Updated Cohort C data and initiation of a Phase 1 study for TSC-102-A01 and TSC-102-A03 are both expected in the second half of 2026.Day One Biopharmaceuticals (NASDAQ: DAWN) announced a definitive acquisition agreement under which Servier will acquire all outstanding shares of Day One Biopharmaceuticals for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The offer price represents a premium of approximately 68% over Day One Biopharmaceuticals' closing price on March 5, 2026, and approximately 86% over its one-month volume weighted average price, reflecting significant value recognition for the company's lead pediatric low-grade glioma program and broader oncology pipeline."Servier's successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One Biopharmaceuticals' mission to bring medicines to patients of all ages with life threatening diseases," said Jeremy Bender, Ph.D., CEO of Day One Biopharmaceuticals. "Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low-grade glioma."The transaction is subject to customary closing conditions, including shareholder tender and U.S. antitrust clearance, and is expected to close in Q2 2026. Day One Biopharmaceuticals' Board of Directors has unanimously recommended that shareholders tender their shares, and Servier expects to fund the acquisition through existing cash and investments.Article Source: usanewsgroup.comCONTACT:USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.pharmiweb.com/press-release/2026-02-19/oncology-market-value-to-more-than-double-reaching-usd-74817-billion-by-2035https://www.openpr.com/news/4395526/immuno-oncology-market-set-for-remarkable-expansion-ashttps://www.foley.com/insights/publications/2025/09/patent-cliff-ma-activity-for-companies-right-now/https://www.pharmexec.com/view/fda-s-new-accelerated-approval-draft-guidanceLogo - https://mma.prnewswire.com/media/2838876/5873016/USA_News_Group_Logo.jpg 





View original content to download multimedia:https://www.prnewswire.com/news-releases/combination-therapies-reshape-oncology-a-748b-market-shifts-standard-of-care-302718641.html

Original: Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

TCRX..................................https://stockcharts.com/sc3/ui/?s=TCRX&p=w&b=5&g=0&id=p86431144783

TCRX: December 6 /25 Press Release

https://finance.yahoo.com/news/tscan-therapeutics-announces-positive-updated-223000522.html

TCRX: ASH 2025 - Poster Presentation

https://www.tscan.com/wp-content/uploads/2025/12/ASH-2025-Poster-Presentation_FINAL.pdf

Amazing data imo.

TCRX....................................https://stockcharts.com/sc3/ui/?s=TCRX&p=W&b=5&g=0&id=p86431144783

Upcoming Anticipated MilestonesThird Quarter 2025 Financial ResultsRevenue: Revenue for the third quarter of 2025 was $2.5 million, compared to $1.0 million for the third quarter of 2024. The increase was primarily due to timing of research activities pursuant to the Company’s collaboration agreement with Amgen.

$1.07 

TCRX: November 2025 Corporate Presentation - MUST READ!

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

TCRX: TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

https://finance.yahoo.com/news/tscan-therapeutics-reports-third-quarter-120000677.html

Well i was hoping to avoid becoming a bagholder here at TCRX, but it's too late now.

I honestly didn't think the update was that bad, however TCRX was brutally punished this past week.

https://finance.yahoo.com/news/tscan-therapeutics-reaches-agreement-fda-113000348.html

Noticed the Aberdeen Group PLC significantly increased their holdings as of 09/30/25

https://www.nasdaq.com/market-activity/stocks/tcrx/institutional-holdings
Aberdeen Group Plc 9/30/2025 1,354,820 463,372 51.98% $1,572

Any thoughts on this institution increasing their holdings? are they in your area?

Thank you

Sponsors will receive early feedback and guidance from the FDA, as well as having more frequent interactions with the agency. It also provides eligibility for priority review and accelerated approval pathways, but it doesn't shorten the trial (duration) itself.

They have now updated the pipeline and include ankylosing spondylitis, ulcerative colitis, and scleroderma programs that are close to lead optimisation.

As for launching the pivotal trial for the heme program, they are leaving it late. I wonder if it will coincide with the data that should be presented at ASH.

Thank you,

The registration trial for TSC-101 seems to be taking a long time, unless of course they need that 2 year trial data
Isn't the RMAT designation intended to fast track things?

They plan to present two-year relapse data on the initial phase one patients, which should be at ASH. Regular abstracts will be available online early next month.

TCRX............................https://www.stockscores.com/charts/charts/?ticker=tcrx

Can we have a daily / weekly / and monthly

Thank you

It's been quiet at Tscan,,, too quiet, imo.

Hear anything about Tscan at ASH 25?

TCRX...............................https://stockcharts.com/h-sc/ui?s=TCRX&p=W&b=5&g=0&id=p86431144783

TCRX: October/25 Company presentation

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

Thank you, looks like the beginning of an auto-immune program.

Looking forward to the heme update and hope the registration trial gets underway soon.

TCRX........................https://stockcharts.com/h-sc/ui?s=TCRX&p=W&b=5&g=0&id=p86431144783

The abstracts are up

TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis

Background/Purpose: Antigen-specific therapies offer a promising approach to selectively modulating autoimmune responses without broad immunosuppression. Strong associations with specific Class I HLA alleles in ankylosing spondylitis (AS) with a linkage to HLA-B*27:05 (Odds ratio of 62) and birdshot uveitis (BU) with a linkage to HLA-A*29:02 (Odds ratio of 157) suggest a role for CD8? T cells, yet the causative autoantigens remain unknown. TScan’s proprietary TargetScan platform offers an unbiased high-throughput method to identify the natural targets of disease-relevant T cell receptors and aid in the development of antigen specific tolerizing modalities.

Methods: We isolated CD8? T cells from synovial fluid of patients with AS and aqueous humor or vitreous humor from patients with BU. Single-cell TCR sequencing identified 42 unique paired a/ß TCR sequences from the ankylosing spondylitis samples and 113 clonotypes from the BU samples. These TCRs, along with 14 previously published TCRs from AS patients, were gene synthesized and screened using the TargetScan platform against a comprehensive cell library representing the full human proteome presented naturally by cells engineered to express the disease associated HLA allele (HLA-B*27:05 for AS, HLA-A*29:02 for BU). Screening revealed multiple putative autoantigen targets which were subsequently evaluated for disease relevance.

Results: Using this approach, we identified over 10 putative Class I–restricted T cell targets for AS and two for BU. These targets were validated through orthogonal assays, including functional T cell activation, and exhibited expression patterns consistent with disease-relevant tissues. Minimal epitopes for each target were mapped to define the core sequences required for TCR recognition. Their identification provides new insight into the antigenic drivers of these conditions and highlights potential avenues for the development of antigen-specific therapeutics.

Conclusion: TScan’s discovery platform enables the identification of novel Class I-restricted autoantigens in autoimmune diseases where no targets were previously known, filling a critical gap in the understanding of T cell-driven pathology. This technology provides a foundation for the development of antigen-specific therapeutics, including tolerogenic approaches aimed at restoring immune homeostasis. https://acrabstracts.org/abstract/targetscan-platform-identifies-targets-of-cd8-t-cells-in-ankylosing-spondylitis-and-birdshot-uveitis/

Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan?

Background/Purpose: Selective modulation of autoimmune responses through antigen-specific therapies represents a promising direction for improving treatment specificity and safety. Genetic associations with HLA class II alleles, combined with evidence of tissue-infiltrating T cells and T cell–mediated cytokine signatures, highlight the central role of CD4? T cells in driving autoimmune pathology. However, the targets of these pathogenic T cells remain poorly defined, limiting development of antigen-specific therapies. TScan’s proprietary TargetScan platform offers an unbiased, high-throughput method to identify natural targets of disease-relevant T cell receptors and support development of antigen-specific tolerizing modalities.

Methods: To identify HLA class II T cell targets for CD4? T cells, the TargetScan platform was adapted to present genetically encoded peptide libraries on ectopically expressed HLA class II molecules. We initially applied this approach to scleroderma. CD4? T cells were isolated from affected skin biopsies of patients and analyzed using 10x Genomics single-cell RNA sequencing. A total of 764 TCRs were identified, with candidates selected for screening based on pathogenic gene expression profiles and CDR3 sequence clustering shared by TCRs found in more than one patient. 61 candidate TCRs were screened for antigen recognition in the context of disease-associated Class II HLA alleles, and identified targets were assessed for disease relevance using follow-up validation assays. Similarly, we used the TargetScan platform to evaluate TCRs from inflamed colon samples derived from patients with ulcerative colitis.

Results: Screening of the candidate TCRs using the Class II TargetScan platform identified eight novel targets presented by multiple HLA Class II alleles associated with scleroderma. These reactive TCRs belonged to shared CD3? clusters found in multiple patients and were characterized by high expression of activation and tissue-homing markers, as well as genes associated with Th2 and Th17 profiles. The identified targets exhibited expression patterns consistent with disease relevance and were validated through orthogonal assays, including functional T cell activation assays. In ulcerative colitis, two novel targets were identified with expression patterns consistent with disease pathology.

Conclusion: TScan’s Class II TargetScan platform enables unbiased identification of novel autoantigens in CD4? T cell–driven autoimmune diseases where antigenic drivers have remained poorly defined. These discoveries may inform the development of antigen-specific therapeutic strategies, including tolerogenic approaches aimed at restoring immune homeostasis. https://acrabstracts.org/abstract/identification-of-novel-hla-class-ii-restricted-autoantigens-in-scleroderma-and-ulcerative-colitis-using-targetscan/

TCRX:TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

https://finance.yahoo.com/news/tscan-therapeutics-announces-upcoming-oral-110000014.html

TScan Therapeutics, Inc.
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025

WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts, one as an oral presentation and another as a poster presentation, at the upcoming American College of Rheumatology (ACR) Convergence 2025 being held October 24 – 29 in Chicago, IL.


“While we remain focused on oncology, our proprietary TargetScan technology is also well suited for identifying novel targets in T cell-driven autoimmune disorders,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “We are excited to present our initial findings at the upcoming ACR Convergence. Among other discoveries, we believe we have identified several shared T-cell targets in Ankylosing Spondylitis. Therapeutic targets for AS have remained elusive despite decades of research and these recent novel discoveries, which are critical to advancing the next generation of therapeutics for autoimmune disorders, highlight the power of our TargetScan technology.”

Oral Presentation Details:

Title: TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis
Authors: Adam Weinheimer, Olivia Pryor, Catalina Burbano, Tyler Heath, Livio Dukaj, Shoshana Bloom, Jackson Lirette, Alexander Cristofaro, Laurie Barefoot, Shrikanta Chattopadhyay, Andrew Ferretti, Cagan Gurer
Abstract Number: 0888
Session Name: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Session Date/Time: Monday, October 27; 10:00 - 11:30 a.m. Central Time
Presentation Time: 10:45 - 11:00 a.m. Central Time
Location: Poster Hall


Poster Presentation Details:

Title: Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan
Authors: Olivia Pryor, Catalina Burbano, Nathaniel Bagge, Rutuja Kulkarni, Heather F Jones, Livio Dukaj, Shoshana Bloom, Jackson Lirette, Candace Perullo, Jinyu Zhu, Teagan Parsons, Ira Jain, Rakshika Balasubramaniyam, Kenneth L Jahan, Vivin Karthik, Alexander Cristofaro, Laurie Barefoot, Shrikanta Chattopadhyay, Kim M Cirelli, Mollie M Jurewicz, Andrew Ferretti, Cagan Gurer
Abstract Number: 0997
Session Name: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
Session Date/Time: Monday, October 27; 10:30 a.m. - 12:30 p.m. Central Time
Location: Poster Hall

TCRX: August 2025 Comapny Presentation - MUST READ!!

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

Q2 https://www.globenewswire.com/news-release/2025/08/12/3131560/0/en/tscan-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update.html

Plans to share initial safety and response data from the PLEXI-T trial won't be until the first quarter of 2026.

TCRX................................................................https://stockcharts.com/h-sc/ui?s=TCRX&p=W&b=5&g=0&id=p86431144783

TCRX: Video of interest

tcrx....................................................https://stockcharts.com/h-sc/ui?s=TCRX&p=W&b=5&g=0&id=p86431144783

tcrx.........................................https://stockcharts.com/h-sc/ui?s=tcrx&p=W&b=5&g=0&id=p86431144783

TCRX:

TCRX under $2

TCRX..........................https://stockcharts.com/h-sc/ui?s=TCRX&p=W&b=5&g=0&id=p86431144783

TCRX, recent 52 week low

tcrx.................................................................https://stockcharts.com/h-sc/ui?s=TCRX&p=W&b=5&g=0&id=p86431144783

TCRX: January 1 2025 Company Presentation

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

https://www.investing.com/news/company-news/tscan-secures-30-million-through-warrant-sale-to-lynx1-93CH-3788868

TCRX: TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

https://finance.yahoo.com/news/tscan-therapeutics-announces-30-million-120000459.html

TScan Therapeutics, Inc.
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per share, representing a premium of 37% to the last closing price of TScan Therapeutics’ common stock, and a 34% premium over the 10-day volume weighted average closing price. The financing is expected to close on or about December 27, 2024, subject to customary closing conditions.


“Lynx1 has been a long-standing and supportive TScan shareholder. We are very appreciative of Lynx1’s continued support and commitment to our mission of delivering life-changing TCR-T cell therapies to patients with cancer, as evidenced by this additional and substantial investment in TScan at a 37% premium,” said Gavin MacBeath, Ph.D., Chief Executive Officer.

“We recently reaffirmed that our cash resources were expected to fund our operations into the fourth quarter of 2026. With the incremental $30M gross proceeds from the sale of these pre-funded warrants, we now expect our cash resources to fund the company’s operations into the first quarter of 2027,” said Jason A. Amello, Chief Financial Officer.

A registration statement on Form S-3 (File No. 333-268260) relating to these securities were filed with the Securities and Exchange Commission (the SEC) on November 9, 2022 and was declared effective by the SEC on May 16, 2023. A final prospectus supplement and accompanying prospectuses relating to the offering will be filed with the SEC. These documents will be available for free on the SEC’s website at http://www.sec.gov.


This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHATM Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-TTM Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.

TCRX: TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

TScan Therapeutics, Inc.
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029

WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank, for up to $52.5 million. The first tranche of $32.5 million, advanced at loan closing, will be used to retire the existing convertible debt with K2 Health Ventures and the remainder for general corporate purposes.


TScan has the option through June 30, 2026, to draw the second $20.0 million tranche, subject to certain conditions and mutual agreement of TScan and SVB. Borrowings under the term loan facility will bear interest at an annual rate equal to the greater of 7.00%, or the prime rate minus 0.75%, subject to an interest rate cap of 9.75%. The term loans will mature on September 1, 2029, and will be subject to monthly interest-only payments until September 30, 2027, provided the Company achieves certain financial and clinical milestones, otherwise the term loans will mature on September 1, 2028, and the interest-only period will be through September 30, 2026.

“We’re pleased to enter into this non-dilutive agreement with SVB which allows us to significantly extend the interest-only period and maturity of our debt financing, providing TScan with added financial flexibility and liquidity,” said Jason A. Amello, Chief Financial Officer. “With this refinancing, we continue to expect our cash resources to fund our current operating plan into the fourth quarter of 2026. We’re looking forward to working with SVB as we deliver on our critical milestones, advance our mission to bring our potential therapies to patients with cancer, and enhance shareholder value.”


“We’re excited to partner with TScan as they advance their innovative hematology and solid tumor programs,” said Lauren Cole, Managing Director with SVB Life Science and Healthcare Practice. “Silicon Valley Bank is thrilled to provide TScan with this refinancing to support their ongoing development efforts to positively impact patients’ lives.”

Further information with respect to the loan agreement is set forth in a Form 8-K filed by TScan with the Securities and Exchange Commission on December 23, 2024.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHATM Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-TTM Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.

About Silicon Valley Bank

Silicon Valley Bank (SVB), a division of First Citizens Bank, is the bank of some of the world’s most innovative companies and investors. SVB provides commercial banking to companies in the technology, life science and healthcare, private equity and venture capital industries. SVB operates in centers of innovation throughout the United States, serving the unique needs of its dynamic clients with deep sector expertise, insights and connections. SVB’s parent company, First Citizens BancShares, Inc. (NASDAQ: FCNCA ), is a top 20 U.S. financial institution with more than $200 billion in assets. First Citizens Bank, Member FDIC. Learn more at svb.com

$3.01 at close December 23/24

TCRX, under $3

Pivotal Study Design.

Through a meeting with the FDA, the Company obtained feedback on the potential registrational pathway following the Phase 1 ALLOHA trial. Based on this feedback, the Company believes that for a registrational trial: (1) the following proposed patient population is acceptable: AML, MDS, and ALL undergoing allo-HCT with RIC, (2) relapse-free survival (RFS) will be an appropriate primary endpoint to support full approval and (3) use of an external control arm using data from Center for International Blood and Marrow Transplant Research (CIBMTR) will be acceptable to support full approval. The Company has decided to pursue an initial registrational path for TSC-101 as it captures almost all HLA-A*02:01-positive patients, and accordingly the Company believes that it is not necessary to include TSC-100 or a companion diagnostic in its upcoming trial. Subject to any further feedback from regulatory authorities or updates to streamline trial execution, the Company expects that the design of a potential registrational trial, which it anticipates launching in the second half of 2025, will include the following elements:



• Subjects: Patients with AML, MDS, ALL undergoing transplant with RIC.



• Donors: Haploidentical and mismatched unrelated donors.



• Enrollment: TSC-101 vs matched controls (1:3)



• Primary endpoint: Relapse-free survival



• Key secondary endpoint: Overall survival, time to relapse and event-free survival



• Exploratory endpoint: Minimal residual disease, complete chimerism rates



• Full approval: the study is designed with a HR of 0.60, 85% power and approximately 140 subjects in the treatment arm. The primary endpoint requires 184 total relapse and death events to assess efficacy



• Study readout: anticipated in approximately 24 months.

Next Steps.

The Company currently intends to focus on the following next steps for its heme malignancies program: (1) continue to enroll ALLOHA Phase 1 study using commercial manufacturing process at the Company, (2) transfer commercial process to a third-party contract development and manufacturing organization (CDMO), (3) work to reach final agreement with FDA on its pivotal trial design and (4) initiate registrational trial with clinical supply manufactured at CDMO.

TCRX: From the recent 8k filing December 9/24

Solid Tumor Program.

TScan is building and expanding the ImmunoBank of T cell receptors (TCRs) to enable enhanced, multiplex TCR-engineered T cell (TCR-T) therapy, which is designed to address the heterogeneity of solid tumors:



• The solid tumor program will focus on immune-rich cancers with high unmet need, with T-Plex enrollment focusing on the following key indications: non-small cell lung cancer (NSCLC), sarcoma, head and neck cancer, and cervical cancer, and anal cancer.


• To date, eight patients have been infused with singleplex TCR-T.



• Early evidence of anti-tumor activity was observed.



• One TCR-T (TSC-203-A0201, which targets PRAME) has advanced through dose level 2 and is now eligible for T-Plex. A second TCR-T (TSC-200-A0201, which targets HPV16) is anticipated to clear dose level 2 before mid-December and will soon be eligible for T-Plex.



• TScan has successfully manufactured its first T-Plex product.



• TScan is progressing multiple TCRs through early does levels, which is expected to enable TScan to investigate multiplexed therapy in 2025.



• Investigational new drug filing for a TCR targeting MAGE-A4 on HLA-A*02:01 (TSC-202-A0201) was submitted, which if cleared is expected to increase T-Plex eligibility.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1783328/000119312524273985/d917413d8k.htm

TCRX: Form 4 filed by Lynx1 Capital Management LP

https://www.sec.gov/Archives/edgar/data/1746376/000090266424006934/xslF345X05/ownership.xml

https://www.sec.gov/ix?doc=/Archives/edgar/data/1783328/000095014224002817/eh240560212_8k.htm

One possibility for the recent share weakness, imo.

As of September 30, 2024, we had cash, cash equivalents and marketable securities of $271.1 million, excluding restricted cash of $5.0 million

Weighted-average common shares outstanding, basic and diluted 118,700,362

Cash value per share at Sept. 30/24 = $2.28

That value will continue to fall as a function of time, only income is collaborative revenue from Amgen.
Unknown at this time for the 4th quarter 2024.

Somebody, (institution possibly) wanted money out of TCRX stock this week.

Next Steps.
The Company currently intends to focus on the following next steps for its heme malignancies program: (1) continue to enroll ALLOHA Phase 1 study
using commercial manufacturing process at the Company, (2) transfer commercial process to a third-party contract development and manufacturing
organization (CDMO), (3) work to reach final agreement with FDA on its pivotal trial design and (4) initiate registrational trial with clinical supply manufactured at CDMO.
Market Opportunity.
The Company believes that if there is an increased use of reduced intensity conditioning with haploidentical donors and mismatched unrelated donors it
would have the potential to expand the addrssable market of its TCR-T therapy candidates, both in the United States and in Europe. The positive data
from the Company’s ALLOHA trial could potentially accelerate such changes in clinical practice and increase the total addressable market. The
Company believes that the addressable market can also be expanded with the introduction of additional TCR-Ts that target other HLA types. TCRs for
additional HLA types will target epitopes on CD45, a universal source of antigens for heme malignancies.
Solid Tumor Program.
TScan is building and expanding the ImmunoBank of T cell receptors (TCRs) to enable enhanced, multiplex TCR-engineered T cell (TCR-T) therapy,
which is designed to address the heterogeneity of solid tumors:
• The solid tumor program will focus on immune-rich cancers with high unmet need, with T-Plex enrollment focusing on the following key
indications: non-small cell lung cancer (NSCLC), sarcoma, head and neck cancer, and cervical cancer, and anal cancer.
• To date, eight patients have been infused with singleplex TCR-T.
• Early evidence of anti-tumor activity was observed.
• One TCR-T (TSC-203-A0201, which targets PRAME) has advanced through dose level 2 and is now eligible for T-Plex. A second TCR-T
(TSC-200-A0201, which targets HPV16) is anticipated to clear dose level 2 before mid-December and will soon be eligible for T-Plex.
• TScan has successfully manufactured its first T-Plex product.
• TScan is progressing multiple TCRs through early does levels, which is expected to enable TScan to investigate multiplexed therapy in
2025.
• Investigational new drug filing for a TCR targeting MAGE-A4 on HLA-A*02:01 (TSC-202-A0201) was submitted, which if cleared is
expected to increase T-Plex eligibility.

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=318776541&type=PDF&symbol=TCRX&cdn=806d13b0878d47ad8d872c82514c5019&companyName=TScan+Therapeutics+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2024-12-10

Pivotal Study Design.
Through a meeting with the FDA, the Company obtained feedback on the potential registrational pathway following the Phase 1 ALLOHA trial. Based
on this feedback, the Company believes that for a registrational trial: (1) the following proposed patient population is acceptable: AML, MDS, and ALL
undergoing allo-HCT with RIC, (2) relapse-free survival (RFS) will be an appropriate primary endpoint to support full approval and (3) use of an
external control arm using data from Center for International Blood and Marrow Transplant Research (CIBMTR) will be acceptable to support full
approval. The Company has decided to pursue an initial registrational path for TSC-101 as it captures almost all HLA-A*02:01-positive patients, and
accordingly the Company believes that it is not necessary to include TSC-100 or a companion diagnostic in its upcoming trial. Subject to any further
feedback from regulatory authorities or updates to streamline trial execution, the Company expects that the design of a potential registrational trial,
which it anticipates launching in the second half of 2025, will include the following elements:
• Subjects: Patients with AML, MDS, ALL undergoing transplant with RIC.
• Donors: Haploidentical and mismatched unrelated donors.
• Enrollment: TSC-101 vs matched controls (1:3)
• Primary endpoint: Relapse-free survival
• Key secondary endpoint: Overall survival, time to relapse and event-free survival
• Exploratory endpoint: Minimal residual disease, complete chimerism rates
• Full approval: the study is designed with a HR of 0.60, 85% power and approximately 140 subjects in the treatment arm. The primary
endpoint requires 184 total relapse and death events to assess efficacy
• Study readout: anticipated in approximately 24 months.

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=318776541&type=PDF&symbol=TCRX&cdn=806d13b0878d47ad8d872c82514c5019&companyName=TScan+Therapeutics+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2024-12-10

Trials looking good!...

stock price not so good.

What's up with that mgmt.?